26
Participants
Start Date
November 12, 2012
Primary Completion Date
November 20, 2014
Study Completion Date
March 21, 2017
Lenalidomide
25 mg of Lenalidomide administered orally once daily
Nagoya City University Hospital, Nagoya
National Cancer Center Hospital East, Kashiwa
Ehime University Hospital, Tōon
Iwate Medical University Hospital, Morioka
Tohoku University Hospital, Sendai
Sasebo City General Hospital, Sasebo
Heart Life Hospital, Nakagami
Shimane University Hospital, Izumo
National Hospital Organization Kyushu Cancer Center, Fukuoka
Kyushu University Hospital, Fukuoka
Imamura Bunin Hospital, Kagoshima
Kagoshima University Medical and Dental Hospital, Kagoshima
National Hospital Organization Kagoshima Medical Center, Kagoshima
Kumamoto University Hospital, Kumamoto
Nagasaki University Hospital, Nagasaki
The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki
Oita Prefectual Hospital, Ōita
National Cancer Center Hospital, Tokyo
Lead Sponsor
Celgene
INDUSTRY